Hefei Lifeon Pharmaceutical Co Ltd (003020) — Working Capital to Net Assets Ratio
Hefei Lifeon Pharmaceutical Co Ltd (003020) has a Working Capital to Net Assets ratio of 34.9% as of March 2026. Working capital of CN¥694.44 Million (current assets of CN¥1.24 Billion minus current liabilities of CN¥542.19 Million) is measured against net assets of CN¥1.99 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 003020 net asset quality score to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Hefei Lifeon Pharmaceutical Co Ltd Working Capital to Net Assets (2012–2025)
This chart shows how Hefei Lifeon Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 34.9%, reflecting working capital of CN¥694.44 Million against net assets of CN¥1.99 Billion CNY. Check 003020 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Hefei Lifeon Pharmaceutical Co Ltd (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Hefei Lifeon Pharmaceutical Co Ltd from 2012 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Hefei Lifeon Pharmaceutical Co Ltd (003020) market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 33.6% | CN¥655.66 Million | CN¥1.95 Billion | CN¥1.18 Billion | CN¥520.58 Million | ▲ +2.0 pp |
| 2024 | 31.6% | CN¥603.54 Million | CN¥1.91 Billion | CN¥1.19 Billion | CN¥581.95 Million | ▼ -0.9 pp |
| 2023 | 32.5% | CN¥608.42 Million | CN¥1.87 Billion | CN¥1.15 Billion | CN¥542.73 Million | ▼ -23.6 pp |
| 2022 | 56.1% | CN¥829.92 Million | CN¥1.48 Billion | CN¥1.45 Billion | CN¥622.63 Million | ▼ -12.3 pp |
| 2021 | 68.4% | CN¥891.59 Million | CN¥1.30 Billion | CN¥1.22 Billion | CN¥328.05 Million | ▼ -12.5 pp |
| 2020 | 80.9% | CN¥949.61 Million | CN¥1.17 Billion | CN¥1.29 Billion | CN¥342.35 Million | ▲ +10.8 pp |
| 2019 | 70.1% | CN¥413.41 Million | CN¥590.00 Million | CN¥694.83 Million | CN¥281.42 Million | ▲ +0.1 pp |
| 2018 | 69.9% | CN¥353.73 Million | CN¥505.70 Million | CN¥605.54 Million | CN¥251.82 Million | ▲ +12.4 pp |
| 2017 | 57.6% | CN¥208.17 Million | CN¥361.71 Million | CN¥439.65 Million | CN¥231.47 Million | ▲ +11.1 pp |
| 2016 | 46.4% | CN¥138.36 Million | CN¥298.09 Million | CN¥375.00 Million | CN¥236.64 Million | ▲ +18.8 pp |
| 2014 | 27.6% | CN¥59.57 Million | CN¥215.53 Million | CN¥313.20 Million | CN¥253.63 Million | ▲ +4.8 pp |
| 2013 | 22.8% | CN¥40.39 Million | CN¥176.88 Million | CN¥307.27 Million | CN¥266.88 Million | ▼ -5.6 pp |
| 2012 | 28.4% | CN¥40.33 Million | CN¥141.96 Million | CN¥256.00 Million | CN¥215.67 Million | — |